L&C Bio Co Ltd
KOSDAQ:290650
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
L&C Bio Co Ltd
Income from Continuing Operations
L&C Bio Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
L&C Bio Co Ltd
KOSDAQ:290650
|
Income from Continuing Operations
₩79.9B
|
CAGR 3-Years
92%
|
CAGR 5-Years
56%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Income from Continuing Operations
₩1T
|
CAGR 3-Years
25%
|
CAGR 5-Years
14%
|
CAGR 10-Years
22%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Income from Continuing Operations
-₩15.7B
|
CAGR 3-Years
18%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Income from Continuing Operations
-₩32.6B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Income from Continuing Operations
₩145.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
61%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Income from Continuing Operations
-₩37.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
L&C Bio Co Ltd
Glance View
L&C BIO Co., Ltd. develops soft tissue, allografts, and medical devices. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-11-01. The firm mainly manufactures and sells human tissue transplant materials used for tissue repair and filler. The firm also produces and sells human tissue-based medical devices and Cosmeceuticals. Its products are used in vascular surgeries, plastic surgeries, general surgeries and others.
See Also
What is L&C Bio Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
79.9B
KRW
Based on the financial report for Sep 30, 2025, L&C Bio Co Ltd's Income from Continuing Operations amounts to 79.9B KRW.
What is L&C Bio Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
56%
The average annual Income from Continuing Operations growth rates for L&C Bio Co Ltd have been 92% over the past three years , 56% over the past five years .
